1. Home
  2. ALLO vs VLN Comparison

ALLO vs VLN Comparison

Compare ALLO & VLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ALLO
  • VLN
  • Stock Information
  • Founded
  • ALLO 2017
  • VLN 2006
  • Country
  • ALLO United States
  • VLN Israel
  • Employees
  • ALLO N/A
  • VLN N/A
  • Industry
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • VLN Semiconductors
  • Sector
  • ALLO Health Care
  • VLN Technology
  • Exchange
  • ALLO Nasdaq
  • VLN Nasdaq
  • Market Cap
  • ALLO 231.9M
  • VLN 224.2M
  • IPO Year
  • ALLO 2018
  • VLN N/A
  • Fundamental
  • Price
  • ALLO $1.05
  • VLN $2.05
  • Analyst Decision
  • ALLO Strong Buy
  • VLN Strong Buy
  • Analyst Count
  • ALLO 10
  • VLN 1
  • Target Price
  • ALLO $8.88
  • VLN $4.00
  • AVG Volume (30 Days)
  • ALLO 5.8M
  • VLN 1.3M
  • Earning Date
  • ALLO 08-13-2025
  • VLN 08-06-2025
  • Dividend Yield
  • ALLO N/A
  • VLN N/A
  • EPS Growth
  • ALLO N/A
  • VLN N/A
  • EPS
  • ALLO N/A
  • VLN N/A
  • Revenue
  • ALLO N/A
  • VLN $66,590,000.00
  • Revenue This Year
  • ALLO N/A
  • VLN $26.28
  • Revenue Next Year
  • ALLO $199.63
  • VLN $16.98
  • P/E Ratio
  • ALLO N/A
  • VLN N/A
  • Revenue Growth
  • ALLO N/A
  • VLN 8.70
  • 52 Week Low
  • ALLO $0.86
  • VLN $1.67
  • 52 Week High
  • ALLO $3.78
  • VLN $3.50
  • Technical
  • Relative Strength Index (RSI)
  • ALLO 38.79
  • VLN 37.02
  • Support Level
  • ALLO $0.99
  • VLN $2.07
  • Resistance Level
  • ALLO $1.21
  • VLN $2.24
  • Average True Range (ATR)
  • ALLO 0.10
  • VLN 0.13
  • MACD
  • ALLO -0.01
  • VLN -0.03
  • Stochastic Oscillator
  • ALLO 20.59
  • VLN 10.08

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.

About VLN Valens Semiconductor Ltd.

Valens Semiconductor Ltd is a provider of semiconductor products, pushing the boundaries of connectivity by enabling long-reach, high-speed video, and data transmission for the audio-video and automotive industries. It operates in two segments: Cross Industry Business, which includes solutions for the non-automotive verticals, including audio-video, industrial, machine vision and medical markets, that deliver superior, plug-and-play convergence and distribution of different interfaces, through a single long-distance category cable; and Automotive segment products enable safe and resilient high-speed in-vehicle connectivity for car architectures, realizing the vision of connected and autonomous cars. The company's geographical revenue is derived from Hungary.

Share on Social Networks: